Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Issues Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) posted its quarterly earnings results on Thursday. The company reported ($2.94) earnings per share (EPS) for the quarter, FiscalAI reports.

Calidi Biotherapeutics Stock Performance

Shares of NYSEAMERICAN:CLDI traded down $0.09 during trading on Thursday, hitting $1.54. 168,390 shares of the company traded hands, compared to its average volume of 229,426. The stock has a market capitalization of $1.86 million, a price-to-earnings ratio of -0.02 and a beta of 1.33. Calidi Biotherapeutics has a one year low of $1.48 and a one year high of $96.95. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.15. The business’s fifty day moving average is $2.17 and its 200-day moving average is $5.36.

Institutional Trading of Calidi Biotherapeutics

A number of large investors have recently modified their holdings of CLDI. Geode Capital Management LLC raised its holdings in shares of Calidi Biotherapeutics by 41.7% during the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after buying an additional 12,334 shares during the last quarter. DRW Securities LLC bought a new position in Calidi Biotherapeutics in the 4th quarter worth approximately $173,000. Finally, Virtu Financial LLC acquired a new stake in Calidi Biotherapeutics in the 4th quarter valued at approximately $25,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.